MB7, strong memory T cell proliferation and inhibition of Treg cell proliferation
Enhanced anti-cancer efficacy is achievable through IL-21v tri-specific fusion protein via 1) proliferation of TCM and TEM cells, and 2) enhancement of TIL quality by inhibition of Treg cell proliferation mechanisms.
αPD-1/novel IL-21v promotes CD8⁺ T cell expansion in activated PBMCs, leading to an enhanced CD8⁺/Treg ratio
- CD8+ T cells
- Treg cells
- CD8+/Treg ratio
Vehicle
Aldesleukin
Pembrolizumab
Ivonescimab
MB7207
MB7, superior anti-tumor efficacy
αPD-1/αVEGF/IL-21v demonstrates superior anti-tumor efficacy in ICI-resistant cancer models compared to αPD-1 or αPD-1/αVEGF antibodies.
- Colon cancer syngeneic model
(C57BL/6 mice, MC38 inoculation, TV ≈ 147mm3 , n=7, ip, BIWx2) 
- NSCLC humanized model
(NCI-H460 inoculation, TV ≈ 86 mm3 , n=6, ip, QWx3) 
